Next Article in Journal
The Impact of Nutrition and Environmental Epigenetics on Human Health and Disease
Next Article in Special Issue
Dynamic Protein S-Acylation in Plants
Previous Article in Journal
Prediction of the Toxicity of Binary Mixtures by QSAR Approach Using the Hypothetical Descriptors
Previous Article in Special Issue
Multiple Aspects of PIP2 Involvement in C. elegans Gametogenesis
Open AccessArticle

Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells

1
Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy
2
Department of Experimental Medicine, University of Perugia, 06126 Perugia, Italy
3
Laboratory of Nuclear Lipid BioPathology, CRABiON, 06122 Perugia, Italy
4
Dipartimento di Area Medica, University of Udine, 33100 Udine, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2018, 19(11), 3424; https://doi.org/10.3390/ijms19113424
Received: 21 September 2018 / Revised: 26 October 2018 / Accepted: 29 October 2018 / Published: 1 November 2018
(This article belongs to the Special Issue Nuclear Lipid Signaling)
Daunorubicin is an anticancer drug, and cholesterol is involved in cancer progression, but their relationship has not been defined. In this study, we developed a novel experimental model that utilizes daunorubicin, cholesterol, and daunorubicin plus cholesterol in the same cells (H35) to search for the role of nuclear lipid microdomains, rich in cholesterol and sphingomyelin, in drug resistance. We find that the daunorubicin induces perturbation of nuclear lipid microdomains, localized in the inner nuclear membrane, where active chromatin is anchored. As changes of sphingomyelin species in nuclear lipid microdomains depend on neutral sphingomyelinase activity, we extended our studies to investigate whether the enzyme is modulated by daunorubicin. Indeed the drug stimulated the sphingomyelinase activity that induced reduction of saturated long chain fatty acid sphingomyelin species in nuclear lipid microdomains. Incubation of untreated-drug cells with high levels of cholesterol resulted in the inhibition of sphingomyelinase activity with increased saturated fatty acid sphingomyelin species. In daunodubicin-treated cells, incubation with cholesterol reversed the action of the drug by acting via neutral sphingomyelinase. In conclusion, we suggest that cholesterol and sphingomyelin-forming nuclear lipid microdomains are involved in the drug resistance. View Full-Text
Keywords: sphingomyelin; cholesterol; nuclear membrane; nuclear lipid microdomains; daunorubicin sphingomyelin; cholesterol; nuclear membrane; nuclear lipid microdomains; daunorubicin
Show Figures

Graphical abstract

MDPI and ACS Style

Codini, M.; Conte, C.; Cataldi, S.; Arcuri, C.; Lazzarini, A.; Ceccarini, M.R.; Patria, F.; Floridi, A.; Mecca, C.; Ambesi-Impiombato, F.S.; Beccari, T.; Curcio, F.; Albi, E. Nuclear Lipid Microdomains Regulate Daunorubicin Resistance in Hepatoma Cells. Int. J. Mol. Sci. 2018, 19, 3424.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop